November 2, 2017
Reliq Health Technologies Announces Closing of Oversubscribed $5 Million Brokered Private Placement
VANCOUVER, BC, November 2, 2017 / - Reliq Health Technologies Inc. (TSXV:RHT or OTCQB:RQHTF)
(“Reliq” or the “Company”), a technology company focused on developing innovative mobile health
(mHealth) and telemedicine solutions for Community-Based Healthcare, is pleased to announce further
to its news releases dated October 11 and 30, 2017, it successfully closed an oversubscribed private
placement (the “Offering”) led by Canaccord Genuity Corp and Gravitas Securities Inc. (together, the
“Co-Lead Agents”) and Beacon Securities Limited (“Beacon” and together with the Co-Lead Agents, the
“Agents”) of 12,500,000 Units (the “Units”) of the Company at a price of $0.40 per Unit (the “Unit
Price”) for gross proceeds of $5,000,000.
Each Unit consists of one (1) common share of the Company (a “Common Share”) and half of one (1/2)
Common Share purchase warrant (each whole Common Share purchase warrant, a “Warrant”). Each of
the 6,250,000 Warrants is exercisable to acquire one Common Share (a “Warrant Share”) for a period of
two years following the closing date of the Offering at an exercise price of $0.60 per Warrant Share,
subject to adjustment in certain events.
“We are very pleased to have completed a successful oversubscribed financing and to have three of
Canada’s leading independent brokerage firms support the Company,” said Dr. Lisa Crossley, CEO of
The Company intends to use the net proceeds of the Offering for general working capital, product
development and customer acquisition.
In connection with the Offering, the Company paid the Agents a cash fee of $340,000 and issued
625,000 Units to the Agents. Additionally, the Company issued 850,000 compensation warrants to the
Agents and other selling dealer group members (the “Compensation Warrants”), with each
Compensation Warrant entitling the holder to purchase one Unit of the Company at an exercise price of
$0.40 for a period of two years following the closing date of the Offering. Each warrant issued under the
Units is exercisable into one Common Share of the Company for a period of two years following the
exercise of the Compensation Warrant at an exercise price of $0.60 per Common Share, subject to
adjustment in certain events.
All securities issued in connection with the Offering are subject to a four month hold period expiring
March 3, 2018.
ON BEHALF OF THE BOARD
“Dr. Lisa Crossley”
CEO and Director
Back to the main Media Room page, or press the Back button on your browser.